Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors.
about
Withdrawal or continuation of cholinesterase inhibitors and/or memantine in patients with dementiaDesigning Second Generation Anti-Alzheimer Compounds as Inhibitors of Human Acetylcholinesterase: Computational Screening of Synthetic Molecules and Dietary PhytochemicalsClinical trials in mild cognitive impairment: lessons for the future.Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.Clinical aspects of inflammation in Alzheimer's disease.Immunization therapy in Alzheimer's disease.Memantine in the treatment of mild-to-moderate Alzheimer's disease.Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.MicroRNA-323-3p with clinical potential in rheumatoid arthritis, Alzheimer's disease and ectopic pregnancy.Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea.Predictors of Response to Cholinesterase Inhibitors Treatment of Alzheimer's Disease: Date Mining from the TREDEM Registry.Cellular responses to nicotinic receptor activation are decreased after prolonged exposure to galantamine in human neuroblastoma cells.Transdermal donepezil on the treatment of Alzheimer's disease.Asian Pacific Islander dementia care network: a model of care for underserved communities.Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine.Use of a novel technology for presenting screening measures to detect mild cognitive impairment in elderly patients.Phyto-Therapeutic and Nanomedicinal Approaches to Cure Alzheimer's Disease: Present Status and Future OpportunitiesNeuroprotective Role of Phytochemicals
P2860
Q24235324-9C164577-F5E4-4424-B380-8A92766C91DDQ28547651-86686657-75ED-40F1-8588-F51A15CA634EQ36142255-CF9F99D7-2489-47AD-9A05-53ED5AD3DAD9Q36349629-1F7CBB7A-0D90-4B95-9705-7D3FB4F5AA2EQ36364213-A385C843-9037-4065-8A07-490C42361ECDQ36492332-AEFDF9A2-FA01-42FA-8421-117C82B857D5Q36719691-626DB89F-87ED-4784-ACCD-A397A94FB68AQ37490737-37642525-F9BF-4B3C-AA44-E3C72E64F4F4Q38166774-47E9F337-BBA1-4265-A812-05906FBECEE4Q38261855-61A01553-55A1-43D7-9676-8E6DC037F035Q38396378-F65F3B86-5224-4A51-86CD-C5FDEACEFB0DQ40413207-2BEDA59C-833A-4990-B015-53B2A38F6B3CQ41786451-B313A7B7-6CAB-4136-ADB9-D32FC755176EQ43811475-1EB5830C-138E-4AC1-ACAC-A382EC55B31DQ45803280-B7978899-3AAC-4AEE-9D86-395817A5B1E1Q48187793-BE3AF6AC-DEB7-4BFD-BD74-9B22DEE2EE88Q58571824-F0C71919-3BF2-40AA-9BA2-00E68B067EBDQ58692870-A293B91A-2AE8-42CF-ABE2-9EBEFA785F7A
P2860
Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Long-term treatment of Alzheim ...... etylcholinesterase inhibitors.
@en
type
label
Long-term treatment of Alzheim ...... etylcholinesterase inhibitors.
@en
prefLabel
Long-term treatment of Alzheim ...... etylcholinesterase inhibitors.
@en
P1476
Long-term treatment of Alzheim ...... etylcholinesterase inhibitors.
@en
P2093
Vesna Jelic
P356
10.1097/01.WAD.0000127495.10774.A4
P407
P478
18 Suppl 1
P577
2004-04-01T00:00:00Z